International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

A Review on Lipid of Nanoparticles.

Komal Sanjay Sonawane.[a], Assistant Prof. Bharti Aher.[b], Dharmraj Eknath Raundal.[c], Neha Pravin Deore,[d], Akshay Rajendra Deore.[e], Yogita Harishchandra Deshmukh.[f]

At. Post: Deothan(422601) Tal: Akole. Dist: Ahmednagar, Maharashtra (India).
Swami Institute of Pharmacy, Abhona Nashik, Maharashtra (India).
Swami Institute of Pharmacy, Abhona Nashik, Maharashtra (India).
Swami Institute Of Pharmacy, Abhona Nashik, Maharashtra (India).
Swami Institute of Pharmacy, Abhona Nashik, Maharashtra (India).
Swami Institute of Pharmacy, Abhona Nashik, Maharashtra (India).

Submitted: 15-02-2023 Accepted: 25-02-2023

ABSTRACT:
As an alternative to other conventional colloidal carriers such liposomes, polymeric nanoparticles, and emulsions due to their benefits such as controlled drug release, focused drug delivery, and enhanced stability, solid lipid nanoparticles were created in the early 1990s. This page provides a summary of the potential benefits and drawbacks of solid lipid nanoparticles, excipients, and all of the many techniques used to make them, including the membrane contractor method. aspects of the stability of SLN and the impact of different excipients (used in the manufacturing of SLN) on stability, as well as other secondary stages involved in their stabilization, such as freeze drying, spray drying, etc. The issues surrounding SLN manufacture as well as the instrumental methods employed are thoroughly examined. Particular focus is placed on drug integration models in SLN and the SLN release pattern. The principal uses of SLNs, namely targeted medication delivery, and the analytical techniques used in SLN evaluations are covered in detail.

Keywords:Colloidal drug carriers, Solid lipid nanoparticles, Solid lipid, Surfactants, Drug incorporation

I. INTRODUCTION: -

For the purpose of guiding site-specific medication distribution, enhancing drug efficacy, and safeguarding active components, numerous drug delivery systems have been created. Drug delivery via nanoparticles has been extensively studied for decades. Solid lipid nanoparticles (SLNs), liposomes, and nanostructured lipid carriers (NLCs) are lipid-based nanoparticles that have shown remarkable clinical efficacy in delivering both hydrophobic and hydrophilic medicines. Docile, a doxorubicin (DOX)-loaded PEGylated liposome for the treatment of breast cancer, ovarian cancer, and other solid tumours, is the first nanodrug to receive FDA approval. By utilising the increased permeability and retention (EPR) effect, PEGylated Liposomal Doxorubicin Dox offers a number of advantages over free DOX, including a significant decrease in cardiotoxicity, an extended retention period in human plasma, and passively tailored delivery to tumours.

However, because of their exceptional biocompatibility, biodegradability, and entrapment effectiveness, lipid nanoparticles (LNPs) have also been acknowledged as a perfect carrier for nucleic acids like DNA, mRNA, and siRNA. The first approved double-stranded LNP-delivering small interfering RNA is called ONPATTRO (2018). Since the 1980s, LNPs with cationic lipids or pH-responsive lipids have been used to encapsulate and distribute nucleic acids. Cationic lipids, however, have unfavourable toxic effects.

Ionizable cationic lipids, which are neutral at physiological pH but have positive charges at lower pH (pH 6.0), are better for creating LNP systems. Ionizable cationic lipids (DLin-MC3-DMA), phospholipids (1,2-Distearoyl-sn-glycero-3-phosphocholine [DSPC]), cholesterol, and lipids modified with polyethylene glycol are the components of LNPs that contain siRNA (PEG2000-C-DMG).Lipid nanoparticles (LNPs) have also been recognised as the ideal carrier for nucleic acids like DNA, mRNA, and siRNA due to their superior biocompatibility, biodegradability, and entrapment efficacy. ONPATTRO is the name of the first authorised double-stranded LNP-delivering small interfering RNA (2018). LNPs

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

containing cationic lipids or pH-responsive lipids have been utilised to distribute and encapsulate nucleic acids since the 1980s. However, cationic lipids have hazardous side effects.

Better for developing LNP systems are ionizable cationic lipids, which are neutral at physiological pH but contain positive charges at lower pH (pH 6.0). The constituents of LNPs that carry siRNA are ionizable cationic lipids (DLin-MC3-DMA), phospholipids (1,2-Distearoyl-sn-glycero-3-phosphocholine [DSPC]), cholesterol, and lipids modified with polyethylene glycol (PEG2000-C-DMG).



Figure1:Nanostructuredlipidcarrier[4].

NLCs also expanded the spectrum and were able to get around many of the drawbacks of traditional lipid-based carriers. For instance, NLCs' physical stability, which is a significant hurdle in emulsion-based formulations, was improved by putting them in a solid state at ambient temperature. The costly technological necessity for mass manufacturing of liposomes was eliminated by the availability of efficient technologies for producing NLCs on a wide scale. NLCs are biocompatible systems that differ from other lipid-based formulations by having a hard morphology that adds to their special qualities.[5]

- **LIPID NANO PARTICLES: WHAT ARE THEY? (6).**
- improved control over the kinetics of an encapsulated compound's release. engineering using lipid composition and size. Melting can act as a catalyst. improved bioavailability of the bioactive that was trapped. Chemical defence of a chemically integrated labile compound a lot less difficult to make than biopolymeric nanoparticles. No unique solvents are needed.
- Numerous basic materials (lipids). Application of traditional emulsion production techniques Similar raw resources are required for emulsions throughout the long run.
- **Types of NLCs:**
- While SLNs and NLSs share a structure, NLCs have three very distinct characteristics. Three alternative techniques were used for the production and formulation of nanostructure NLCs, and their features depend on the location the medicine will be integrated (7).NLC type also called as imperfect crystal.
- NLC type also called as amorphous type.

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781



Figure2 - Structures if nanostructure lipids carriers [7]

NLC kind is also known as flawed crystal.

The solid matrix of NLC type I, also known as imperfect crystal types, is poorly organised. Glycerides are one type of fatty acid that can be used to improve and alter the structure. The total number of flaws in the structure is both responsible for and beneficial for the ability of a good drug to be improved.



Figure3: Crystallization processduringstoragetoperfect crystalin SLN(left)and unchanged remainingNLCIstructurewith imperfections[6].

• **Kind II NLC is sometimes referred as as amorphous type**.

The lipids are blended in this method of making NLCs so that crystallization can be avoided by the mixing process. The lipid matrix is still solid but amorphous in the type III procedure. Drug ejection is frequently caused by the crystallization process and methodology. To lessen this, solid lipids such isopropyl palmitate, MCT, or hydroxy lactose hydroxyl stearate can be carefully blended with solid lipids to create NLCs. although nanocrystalline NLC are produced in solids (4,8).

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

The Type II device has the advantages of a high drug entrapment efficiency, controlled drug release, and minimum drug leakage. [9]



Figure4: Structure less type II of NLC the lipid solidifies in the solid but amorphous [6].

The oil-in-lipid-in-water kind of NLC is known as a multiple type and belongs to the II category of NLCs.

The solubility of oil is higher in type II NLCs than that of solid lipids [10]. Due to the oil molecule's ease of spreading into the lipid matrix at low oil concentrations, type II NLCs include substantial amounts of oil mixed with solid lipids [6].

If more oil is injected than is necessary for it to dissolve, this can cause the separation of distinct phases, which ultimately results in the formation of tiny oily nano compartments that are enclosed by the solid lipid matrix [4].



Figure 5: Theoretical proposed structure of multiple type NLC (oil-in-solid fat-in-water) (O/F/W) [6]. Of Because their highly disordered lipid structures, NLCs can accept pharmaceuticals. Because of their highly disordered lipid structures, NLCs can accept pharmaceuticals [11].

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

CharacterizationofNLCs

ZetaPotential: -

The zeta potential (ZP) indicates the overall charge a particle acquires in a specific medium.Stability of the nano dispersion during storage can be predicted form the ZP value. The ZPindicates the degree of repulsion between close and similarly charged particles in thedispersion. High ZP indicates highly charged particles. Generally, high ZP (negative or positive)preventsaggregationof theparticlesduetoelectricrepulsionandelectrically stabilizesthe nanoparticle dispersion. In terms of rate of incorporation, neither SLN nor NLC lipid nanoparticles outperformed typical nano emulsions. [(12).] With increasing oil content, the zeta potential value of SLNs and NLCs has increased [(13).]

Cooling procedure of a hot homogenization process [n the other hand, in case of low ZP, attraction exceeds repulsion and the dispersion coagulates or flocculates. However, this assumption is not applicable for all colloidal dispersion, especially the dispersion which contain steric stabilizers. The ZP value of −30 mV is enough for good stabilization of a nano dispersion.TheZP of the nano dispersions can be determined by PCS[(14).]

Particle Size:-

Particle size was determined by particle size and zeta potential PCS. [(15)] The reticuloendothelial system's ability to absorb and remove particles from the gastrointestinal tract depends critically on their size. Therefore, it is crucial to determine the particle size precisely. For intestinal transit, it is best to use particles that are smaller than 300 nm [(16)]. The most effective and popular methods for determining the particle size of lipid nanoparticles are photon correlation spectroscopy and laser diffraction. Another name for PCS is dynamic light scattering. This method measures the variation in scattered light intensity brought on by particle mobility. PCS is a method that is sensitive and reasonably accurate. However, PCS can only measure objects up to around three nanometers in size [(17)]. For lipid nanoparticles to be described, this size range is sufficient. However, LD is able to quantify larger particle sizes (>3). From the nanoscale to the lower millimeter level, LD spans a wide size range. The foundation of this approach is the relationship between the diffraction angle and particle radius. In comparison to bigger particles, smaller particles exhibit more intense scattering at high angles. [(18)] However, as both approaches estimate particle sizes from their light scattering effects rather than actually measuring particle sizes, it is generally advised to employ both PCS and LD together. This is due to the fact that many times, particles are not spherical [(14)].

Crystallinity and Polymorphism:-

Determining the crystallinity of the ingredients in SLN/NLC formulations is important because the lipid matrix and the medicine it contains may go through a polymorphic transition that could result in unwanted drug ejection during storage. Drug incorporation and release rates are also highly associated with lipid crystallinity. Drug in corporation rates drop in the following order: super-cooled melt, modification, modification, and modification. Thermodynamic stability and lipid packing density increase. However, due to the small size of the particles and the presence of emulsifiers, lipid crystallization and alteration changes may be significantly slowed down. To ascertain the crystallinity and polymorphic behavior of the constituents of the SLNs/NLCs, two extensively utilized techniques are differential scanning calorimetry (DSC) and X-ray diffractometry (XRD) [(19).] In contrast to XRD, which may identify certain crystalline compounds based on their crystal structure, DSC offers information on the melting and crystallization behavior of all solid and liquid constituents of the particles. [(20)]

DSC takes advantage of the fact that various lipid changes have various melting points and melting enthalpies. In XRD, a monochromatic X-ray beam is diffracted at angles dictated by the distance between crystallographic planes and the kind and arrangement of the atoms, and this pattern is captured by a detector. Each form of crystalline material has a different diffraction pattern, both in terms of its intensity and location. An XRD pattern can characterize and identify the structure of lipid and drug molecules, as well as forecast how lipid molecules would be arranged and behave in phases.

The direct investigation of SLN dispersions, however, yields the best results because solvent removal may alter the alteration. Raman and infrared spectroscopy are two other methods that are helpful for examining the structural characteristics of lipids. However, they have not been employed frequently to describe SLNs/NLCs.[(21)]

Specific restrictions:

Such as cytotoxic effects based on matrix

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

type and concentration, certain surfactants' irritative and sensitizing effects, It is still necessary to improve application and efficiency for gene delivery systems and medications based on proteins and peptides. and Insufficient preclinical and clinical research has been done on these nanoparticles for bone healing. Natural essential oils are gaining popularity as antimicrobials due to consumer demand for food free of synthetic additives. [23].

Componentof the NLCLipids:-

The main component of NLC is lipid, which affects how well they can load drugs, how stable they are, and how they behave during continuous release. Lipid nanoparticle dispersions are created using a variety of lipid components, including fatty acids, glycerides, and waxes. The bulk of these lipids, with the notable exception of acetyl palmitate, have received approval as generally regarded as safe (GRAS) and are physiologically well-tolerated [24]. It's crucial to pick the best lipids before employing them to create lipid nanoparticle dispersions.

Although there are no exact standards, empirical information like medicine solubility in lipid has been offered as an important factor to consider when choosing an appropriate lipid.[25]The main component of NLC is lipid, which affects how well they can load drugs, how stable they are, and how they behave during continuous release.

Lipid nanoparticle dispersions are created using a variety of lipid components, including fatty acids, glycerides, and waxes. The bulk of these lipids, with the notable exception of acetyl palmitate, have received approval as generally regarded as safe (GRAS) and are physiologically well-tolerated [26]. It's crucial to pick the best lipids before employing them to create lipid nanoparticle dispersions.

Although there are no exact standards, empirical facts, such as the solubility of medications in lipid, have been offered as relevant standards for choosing an appropriate lipid [4].

Solid lipids:-

A combination of numerous chemical compounds which have a melting point higher than40°C.

Examples are beeswax, carnaubawax,dynasan,precifac,stearicacid,ppifil,cutinaCP8 etc.

Liquid lipids(oil):-

These liquid lipids are well tolerated and accepted for human use.

Examples are castor oil, oleic acid, palm oil, olive oil etc. as shown inTable1.

Table1: Lipids used in the preparation of nanostructured lipid carriers [2,8].

Fatty acids	Do decanoic acid, Myristic acid, Palmitic acid And Stearic acid.
Monoglycerides	Glyceryl monostearate, and Glyceryl behenate.
Diglycerides	Glyceryl palm it Glyceryl Di behenate
Triglycerides	Caprylate triglyceride, Caprate triglyceride, Glyceryl and tri behenate
Waxes	Carnauba, and wax Beeswax
Liquid lipids	Soyabean oil, Oleic acid.

EMULSIFYING AGENTS-

Surfactants are adsorbing molecules at interfaces that aid in reducing interfacial tension. Surfactants, commonly referred to as surface-active agents, improve stability by reducing surfactant rate when they are present in small quantities. Low

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

concentrations of surfactants cause them to adhere to an interface or system's surface. Surface tension or interfacial tension is decreased by surfactant.

The mixture of solid and liquid-lipid mixes won't do much to aid in perfect crystallisation in the case of NLC formulation. Researchers lessened the possibility that the encapsulated medication would be ejected during storage to address this problem. The addition of polysorbate 80 may have provided more interfacial area than polysorbate 20. As a result, NLC's 80 had a smaller average size than NLC's 20.

As a result, the average size of NLC's 80 was smaller than that of NLC's 20. The properties of NLCs can vary depending on the type of surfactant used in the formulation. The type of stabiliser had a significant impact on the NLCs' average size and charge, but not their size dispersion [28].

NLCs have special qualities and traits that make it possible to deliver a variety of integrated pharmacological forms. The properties of NLCs are significantly influenced by the type of surfactant used. Energy is conserved by lowering the surface or interfacial tension between the two phases.

The many surfactant kinds and classifications are listed in Table 2. The mode of administration of NLCs and the surfactant's HLB value are two factors that are taken into consideration while selecting surfactants for NLCs. The surfactants and co-surfactants are listed in Table 2. the impact of surfactant concentration on NLC particle size and dispersion NLC is stable because of the steric and electrostatic attraction between the particles. Some steric repulsion and electrostatic properties are described. The separation distance between the internal and exterior aqueous phases, the thickness of the to words or bed surfactant layers, and the size of the internal aqueous droplets and the oil globules all affect how much the adsorbed surfactant molecules are compressed.To properly achieve the thickness of each of the two surfactant layers, thicker adsorbed layers must be employed [28].

Surfactants	
Ionic surfactants	Non-ionic surfactants
Sodium deoxy cholate, Sodium oleate,	Span20,80,85, Tween20,80,Tyloxapol, Poloxamer188Poloxamer407, SolutolHS15
Amphoteric surfactants	Co-surfactants
Egg phospholipid (LipoidE80, LipoidE80S) Soy Hydrogenated soy phosphatidylcholine (LipoidSPC-3, Hydrogenated egg phosphatidylcholine (LipoidEPC-3) Phospholipon80H, Phospholipon90H)	Butanol, Butyric acid

Table:2 List of Surfactant

To avoid the internal aqueous droplets combining with the outer aqueous phase, prevent this from happening. A more stable double emulsion system can be created by preparing the system with smaller oil globules and larger internal aqueous droplets. Smaller oil globules and bigger internal aqueous droplets provide more steric repulsion than larger oil globules.

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

Systems are stabilised by polyhydroxy surfactants by spatial exclusion, and because of their non-ionic makeup, low and zero zeta potential are achieved. It is claimed that the continuous phase's ionic strength and the charge density on the surface of the water and fat have an impact on how stable nanolipid carriers are with regard to aggregation [28].

Surfacemodifiers

Polyethylene glycol 2000 coupled with dipalmitoyl-phosphatidylethanolamine (DPPE-PEG2000). 2000 Di stearoyl-phosphatidylethanolamine-N-poly (DSPE-PEG2000)
Stearicacid-PEG2000(SA-PEG2000).

mPEG5000-C-LAA18 is an acronym for -methoxy-PEG 5000-carboxylic acid-lipoamino acids.
Dextran sulphate sodium salt, an ionic polymer.

Methods of preparation-

For the manufacturing of SLNs and NLCs, a variety of formulation procedures are available. Among them, high-pressure homogenization (HPH) and microemulsion procedures have proven to have a significant degree of scaling potential. The various current methods for SLN and NLC formulations are described in the sections that follow. But in certain cases, a mixture of various techniques has been used to make the nanoparticles (14).

Methods of preparation-

A variety of formulation techniques can be used to produce SLNs and NLCs. For scaling up to industrial production levels, high-pressure homogenization (HPH) and microemulsion techniques have shown a lot of promise. The sections that follow provide descriptions of the various approaches that are currently employed to formulate SLN and NLC. However, a variety of approaches have occasionally been combined to make the nanoparticles (14). Aqueous NLC was created using the method outlined by Muller and coworkers. As a result, phase heated to 10-15 degrees.[29] NLCs can be made in large quantities utilising techniques that are generally well-established, such as dispersing techniques that do not require organic solvents. For these techniques, there are two distinct homogenization methods: high-temperature, high-pressure and low-temperature, high-pressure. More typically, high-temperature, high-pressure homogenization is employed, which involves first melting the solid lipid components before adding the liquid lipid and drugs. Following mixing, the molten liquid is distributed throughout the aqueous phase that contains surfactants. The mixture is stirred to produce the initial phase of an emulsion. Then, under extremely high shear stress, high-speed impact and decompression expansion gradually separate fluid droplets into nanoparticles. The viscosity of the combined liquid normally decreases at high temperatures, which reduces particle size but raises the possibility that the medication and the carrier will deteriorate. While this method works well for insoluble and lipophilic medications, it performs less well for hydrophilic ones. Avoiding organic solvents and larger-scale manufacture are two advantages.

Hothigh-pressurehomogenization:

This procedure involves dissolving or evenly dispersing the drug in the melted lipid(s) at a temperature that is 5 to 10 degrees Celsius over its or their melting point (s).

Next, a hot, previously heated aqueous surfactant solution is combined with the drug-lipid melt at the same temperature, and the mixture is homogeneously disseminated (pre-emulsed). In a high-pressure homogenizer, this hot pre-emulsion is subsequently heated to the same temperature [30].The homogenization process is repeated until the nano emulsion's average particle size is as required. The nano-emulsion is produced and cooled to room temperature. Lipid droplets in the nano emulsion re-crystallize as it cools, forming lipid nanoparticles with a solid matrix [14].

Cold high-pressure homogenization

In the cold HPH approach, which is comparable to hot HPH, the lipid(s) is/are melted at 5–10 °C above its/their melting temperatures, and the drug is/are dissolved or homogeneously dispersed in the melted lipid (s). After being immediately cooled down with dry ice or liquid nitrogen, the drug-lipid melt is next crushed into tiny pieces in a ball mill or mortar. By suspending these minuscule particles in a cold aqueous surfactant solution, they are then homogenised at or below room temperature to produce lipid nanoparticles. This approach is appropriate for hydrophilic or thermo-labile medications since it is expected to reduce temperature-induced drug breakdown and drug dispersion into aqueous phase during homogenization.However, it is impossible to totally prevent this because the medication must

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

be exposed to high temperatures. The material is dispersed or dissolves in the molten lipid as a result of the homogenization process, which also generates some heat. Increasing a process usually brings forth a number of problems (31). A product with even greater quality in terms of finer particle size and homogeneity is produced during HPH, though, by employing larger scale machines. Additionally, the food and pharmaceutical industries are well-known for and frequently use the HPH technique. HPH can also produce SLN in non-aqueous dispersion media if the dispersion medium, such as liquid polyethylene glycol or oils (such as mineral oil), does not dissolve the lipid [14] .



Figure6-PreparationofNLCsbycoldandhothigh-shear

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

Ultrasonication:

High-speed homogenization or ultra-sonification is another method for creating SLNs. The advantage of this method is that it makes use of tools that are routinely used at lab scale. This method, however, has disadvantages, such as a greater size dispersion that extends down to the micrometre range. Potential metal contaminations and physical instability, such as the production of particles during storage, are additional drawbacks of this approach [33,34].

Micro-emulsiontechnique

Using this technique, the lipids are melted, and the drug is then added to the liquid lipid. A mixture of water, co-surfactant(s), and surfactant that has been heated to the same temperature as the lipids is added together with the lipid melt. A transparent, thermodynamically stable system is produced when the ingredients are mixed in the ideal ratios for microemulsion formation. The development of nanoparticles with the requisite size begins with the creation of the microemulsion. To disperse the heated microemulsion in a cold aqueous medium, water is mechanically gently diluted with the hot microemulsion in a 1:25-2:50 ratio. The dispersion in the cold aqueous solution causes the oil droplets to immediately recrystallize [5].Lecithin and biliary salts are, respectively, co-surfactants and surfactants. Along with alcohol, there is butanol. Excipients like butanol are less frequently employed because to the regulatory consequences. The microemulsion is prepared in a large temperature-controlled tank, and the contents are pumped into a cold-water tank for the precipitation stage [24].

Solventemulsification-evaporationtechnique:

Lecithin and biliary salts are, respectively, co-surfactants and surfactants. Along with alcohol, there is butanol. Excipients like butanol are less frequently employed because to the regulatory consequences. The microemulsion is prepared in a large temperature-controlled tank, and the contents are pumped into a cold-water tank for the precipitation stage [24].

In both aqueous and oligogenic phases, where the solvent must be slightly soluble in water, this approach can be used. The solvent and water must initially reach mutual saturation in order for the initial thermodynamic equilibrium of both liquids to be guaranteed. The heating process that is utilised to solubilize the lipid is carried out at the same temperature as the saturation. The drug and lipid were subsequently dissolved in a water-saturated solvent, and this organic phase was produced [14].

SolventDispersion: -

In the solvent dispersion method, solid lipid, liquid lipid, and the drug are all dissolved using a water miscible organic solvent (ethanol, acetone, or isopropanol). The organic solution is then gradually infused into the water containing the emulsifier, and the NLC is extracted using centrifugation. The amount of medication placed into NLCs created using this method often depends on the liquid's volume. To further enhance the drug loading of NLC, the dispersed phase is often utilised to surround a saturated drug solution. The advantages of this strategy include speed, simplicity, and a low instrument requirement. This method has limitations because it still contains organic solvent and isn't entirely suitable for commercial manufacture [35].

The solvent also prepares NLCs dispersion strategy This approach was applied. In order to achieve an entrapment efficiency of paclitaxel7211.6%, they were made with cholesterol as the solid lipid, OA as the liquid lipid, and poloxamer188 and polysorbate 80 as surfactants. 3.1.4[2].

Film-Ultrasonic Method

In the film-ultrasonic method, the medications, solid lipids, and liquid lipids are dissolved in a suitable organic solvent before being eliminated by vacuum evaporation. The application of a layer of mixed lipid films requires the use of a surfactant aqueous solution. Then, using an ultrasound probe, small and reliable NLCs are produced by ultrasonic dispersion. This method is most frequently used since it is simple, practical, and produces small, homogeneous particles. However, the product made utilising this procedure could have toxicological problems due to solvent residues [2].

Applications

Applications for NLCs as nano lipid carriers can be found in many different industries. The applications are broken down into two categories that are more general: the therapeutic applications, which cover the numerous drug delivery pathways, and the applications in other industries, such as cosmetics, nutraceuticals, food, chemotherapy, and gene delivery. Below is a discussion of them:

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

Therapeutic applications topicaldelivery

Topical drug delivery to cutaneous regions has frequently used lipid-based nanoparticles. Recently, numerous studies and tests on the practical application of NLCs for their unique properties have been carried out [(36)]. The apparent solubility of drugs that are retained by NLCs can be increased, creating a significant concentration gradient on the skin that facilitates the penetration of pharmaceuticals. Due to the nano-sized particles' strong adherence to the surface of the skin, drugs are delivered more gradually and under strict supervision [(37)]. In order to increase penetration and prolong release, several different categories of drugs are applied topically using NLCs.

The rapid time required for these products to enter the market is another benefit of NLCs for topical delivery of active compounds [(22)]. Neither SLN nor NLC lipid nanoparticles outperformed ordinary nanoemulsions in terms of rate of incorporation [(38).]

Oraldelivery

NLCs have been demonstrated to be one of the advantageous systems for oral administration of medicines with limited bioavailability and poor water solubility. Large dispersion of NLCs, which results in a high specific surface area for enzymatic assault by intestinal lipases, is another crucial characteristic (39). Increased drug loading, enhanced drug inclusion, patient compliance, high particle concentration, and cream-like carrier consistency are further benefits of administering NLC orally [(33)].

Parenteraldelivery

Lipid-based nanoparticles have been employed extensively for topical medication delivery to cutaneous areas. Numerous investigations and testing on the use of NLCs in practical settings for their distinct features have recently been conducted (36). Pharmaceuticals can more easily penetrate the skin by establishing a substantial concentration gradient on the surface thanks to an increase in the apparent solubility of medications that are held by NLCs. Drugs are administered more gradually and under precise control because of the strong adhesion of the nano-sized particles to the skin's surface (37). Several distinct categories of medications are delivered topically utilising NLCs to improve penetration and prolong release.

The quick commercialization of these products is another advantage of NLCs for topical administration of active chemicals (22). Regarding the rate of increased cytotoxicity and hemolytic activity with less negative effects when used in corporate NLCs (22,40).

Ocular drug delivery

The administration of ophthalmic medications with prolonged pre-corneal retention durations and high penetration into aqueous humour and intraocular tissues is the key limiting factor for treating ocular illnesses and disorders. Recent studies suggest that the administration of NLC may increase the bioavailability of the lipophilic drug ibuprofen to the eyes [(43)]. Our earlier research showed that NLC might improve the uptake of bioactive compounds into ocular tissues while preserving a tolerable level of ocular tolerance. Another method is to strengthen the formulation of an NLC by adding permeation enhancers such as transductal IP and Gelu Cire 44/14, two types of solid lipids that can somewhat increase drug corneal permeability while stearyl Amine can lengthen pre-corneal retention of medication.The preparation demonstrated greater bioavailability when compared with eyedrops and all three materials can be used to improve the formulation of an NLC ocular medication delivery [(22)].

Mucoadhesive nanostructured lipid is another promising carrier for the in vitro and in vivo administration of eye medications. An in vivo distribution investigation found that thiolate NLC might extend pre-corneal residence time and distribute high quantities of cyclosporine (CVA) to eye tissues in the ocular surface and anterior chamber [(22)].

Drugdeliverytobrain

Brain targeting raises the drug's concentration in cerebrospinal fluid while reducing the frequency of dose and side effects. The avoidance of first pass metabolism and the rapid onset of action are this form of administration's key advantages over oral administration. LNC (for instance, NLC) of this generation are recognised as one of the important strategies for drug delivery without any change to the drug molecule due to their fast absorption by the brain, bioacceptability, and biodegradability. They are also more promising scale-up candidates and don't exhibit the burst effect, which increases their potential as drug delivery vehicles. NLC also enhanced the way duloxetine is administered intranasally to the brain in order to treat major depressive

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

disorder.medication used to increase dopamine Receptor agonist has also been added to NLCs for regulated drug administration in pulmonary drug delivery to provide long-lasting therapeutic effects and might extend BC half-life in vivo for the treatment of Parkinson's disease [22,33].localised drug concentrations In pulmonary drug delivery systems, surfactants and co-solvents are also used to develop stable formulations of very lipophilic active ingredients [44].

Few attempts have been made to administer anti-cancer medications via inhalation using nanoparticles and liposomes, but the primary challenges were instability during nebulization, biodegradability, drug leakage, and undesirable side effects. The majority of the nebulized nanoparticles were able to settle in the mice lungs' alveolar region, lengthening the duration of celecoxib lung residency. Using a combination of solid and liquid lipids, the lipophilic COX-2 inhibitor celecoxib was successfully encapsulated in the NLC nanoparticles. In order to prevent drug deposition in the upper airways and exhalation while medications are being deposited in the deep lung, ultrafine particles must be controlled.[44]

Other applications Cosmetics

Recently, NLCs were produced by carefully regulating the nano-structuring of the particle matrix, which has great advantages for loading capacity and long-term stability [45]. Improved skin absorption of active ingredients, film generation and controlled occlusion, UV protection, penetration augmentation and epidermal targeting, improved physical and chemical stability, and in-vivo skin hydration are all benefits of employing these NLCs in cosmeceuticals [22].

NLCs considerably increased oxybenzone's in vitro SPF and erythemal UVA protection factor by more than six and eight times, respectively, with less side effects. According to studies, NLC with CutanovaCreamNanoRepairQ10 hydrates skin more effectively than a conventional o/w cream of the same composition. Nano Lipid Restore CLR is a different cosmetic item based on lipid nanoparticles. NLCs are given a boost in stability and oxidation resistance by the addition of the readily oxidised black currant seed oil. Another Sturm product increases the occlusive properties of a day cream without changing how light it is, resulting in higher occlusive features without making the skin look shiny. Additionally, by integrating the minimum NLCs, a prolonged release profile for the scents and in sect repellent was created [22].

Chemotherapy

Recent research has demonstrated that NLCs not only improved the efficacy and stability of several cytotoxic medicines, but also decreased their negative effects. In early 2005, the albumin-paclitaxel nanoparticles were approved for use in chemotherapy for metastatic breast cancer. Etoposide NLCs were also discovered to be cytotoxic against human epithelial-like lung carcinoma cells, and topotecan NLCs were stabilised and released for a prolonged period of time to treat refractory ovarian and small-cell lung cancer. High drug loading efficiency, a delayed release profile, enhanced chemical stabilisation, and increased cytotoxicity are benefits of using anti-cancer medications in NLCs [22].

Nutraceuticals are bioactive substances that provide pharmacological or health benefits, such as the ability to treat and prevent disease. Due to their widespread distribution in plant tissues, structural variety, and extensive range of functions, carotenoids are one of the most significant classes of natural pigments [22].

II. CONCLUSIONS

With fewer side effects, NLCs significantly enhanced oxybenzone's in vitro SPF and erythemal UVA protection factor by more than six and eight fold, respectively. Studies show that NLC moistened skin more effectively than a conventional o/w cream with the same formulation when it contained CutanovaCreamNanoRepairQ10. Nano Lipid Restore CLR is the name of a separate cosmetic item based on lipid nanoparticles. NLCs are given the quickly oxidised black currant seed oil to boost their stability and oxidation resistance. Another Sturm product enhances a day cream's occlusive properties without changing its lightness, resulting in improved occlusive qualities without making the skin look glossy. Additionally, a prolonged release profile for conventional nano emulsions showed neither SLN nor NLC lipid nanoparticles to be beneficial.

REFERENCE-

[1]. M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler, N. A. Peppas, R. Langer, Nat. Rev. Drug Discov.2021, CrossrefCASPubMedWeb of Science®Google Scholar

[2]. 2A. Gordillo-Galaneano,C.E. Mora-Huertas, Eur. J. Pharmaceutical.

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 1 Jan-Feb 2023, pp: 2145-2159 www.ijprajournal.com ISSN: 2249-7781

Biopharm. 2018, CrossrefCASPubMedWeb of Science®Google Scholar

[3]. 3J. K. Patra, G. Das, L. F. Fraceto, E. V. R. Campos, M. del Pilar Rodriguez-Torres, L. S. Acosta-Torres, L. A. Diaz-Torres, R. Grillo, M. K. Swamy, S. Sharma, J.Nanobiotechnoble. 2018, Crossr efPuMedWeb of Science®Google Scholar

[4]. 4P. Yingchoncharoen, D. S. Kalinowski, D. R. Richardson, Pharmacology. Rev.

[5]. HaiderM, Abedin SM,KamalL, Orvie G.Nano structured lipidcarriers fordeliveryofchemotherapeutics: Areview.Vol.12,Pharmaceutics.MDPI AG; 2020.

[6]. Patel DK, Tripathy S, Nair SK, Kesharwani R. NANOSTRUCTURED LIPID CARRIER(NLC) A MODERN APPROACH FOR TOPICAL DELIVERY: A REVIEW LipidNanoparticle based drug delivery system View project Dyspepsia View project Dilip K PatelGovernment Polytechnic Jumper NANOSTRUCTURED LIPID CARRIER (NLC) AMODERNAPPROACHFORTOPICAL DELIVERY:AREVIEW[Internet]. availablefrom:www.wjpps.com

[7]. ElmowafyM,Al-SaneaMM.Nanostructuredlipidcarriers(NLCs)asdrugdeliveryplatform:Advances in formulation and delivery strategies. Vol. 29, Saudi Pharmaceutical Journal.ElsevierB.V.; 2021.p.999–1012.

[8]. Sharma A, Baldi A. Nanostructured Lipid Carriers: A Review Comprehensive regulatoryguidelinesforRadiopharmaceuticalsViewprojectArtificialIntelligenceforherbaldrugsViewproject Nanostructured Lipid Carriers: A Review. 2018; Available from:https://www.researchgate.net/publication/33207371826.

[9]. Chauhan I, Yesim, Verma, SinghAP. Nanostructured lipid carriers: A ground breaking approach for transdermal drug delivery. Vol. 10, Advanced Pharmaceutical Bulletin. TabrizUniversityof MedicalSciences;2020.p.150–65.

[10]. Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery.Vol.103, Bio medicine and Pharmacotherapy. Elsevier Masson SAS; 2018.p.598–613.

[11]. Selvamuthukumar S, Velmurugan R. Nanostructured Lipid Carriers: A potential drug carrier for cancer chemotherapy.Vol.11, Lipids in Heathland Disease. Bio Med Central Ltd.;2012.

[12]. Fang G, Tang B, Chao Y, Xu H, Gou J, Zhang Y, et al. Cysteine-Functionalized Nanostructured Lipid Carriers for Oral Delivery of Docetaxel: A Permeability and Pharmacokinetic Study. Molecular Pharmaceutics.2015 Jul6;12(7):2384–95.

[13]. Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid Nanoparticles asCarriersforBioactiveDelivery.Vol.9, Frontiers in Chemistry.FrontiersMediaS.A.;2021.

[14]. DasS, Chaudhury A. Recent advance since lipid nanoparticle formulations with solid matrix for oral drug delivery.Vol.12,AAPSPharmSciTech.2011.p.62–76.

[15]. Kovačević AB, Müller RH, Keck CM. Formulation development of lipid nanoparticles: Improved lipid screening and development of tacrolimusmusaloadednano structured lipid carriers (NLC). International JournalofPharmaceutics.2020 Feb25;576.

[16]. Kawadkar J, Pathak A, Kishore R, Chauhan MK. Formulation, characterization and in vitro-in vivo evaluation of flurbiprofen-loaded nanostructured lipid carriers for transdermal delivery. Drug Development and Industrial Pharmacy.2013Apr;39(4):569–78.

[17]. Wu M, Fan Y, Lv S, Xiao B, Ye M, Zhu X. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Delivery.2016Oct12;23(8):2720–5.

[18]. Awadeen RH, Boughdady MF, Meshali MM. Quality by Design Approach for Preparation of Zolmitriptan/Chitosan Nanostructured Lipid Carrier Particles - Formulation and Pharmacodynamic Assessment. IntJNanomedicine.2020;15:8553–68.

[19]. Das S, Ng WK, Tan RBH. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers: I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole- loaded nanoparticles.Nanotechnology.2014 Mar14;25(10).

[20]. Date AA, Vador N, Jagtap A, Nagarsenker MS. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: Fabrication, characterization and evaluation for oral drug delivery. Nanotechnology. 2011Jul 8;22(27).

[21]. Gordillo- Galeano A, Mora-Huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release. Vol. 133, European Journal of Pharmaceutics and Biopharmaceutics.ElsevierB.V.;2018.p.285–308.

[22]. Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application integrated drug delivery. Vol. 44, Artificial Cells, Nanomedicine and Biotechnology. Taylor and Francis Ltd.;2016.p.27–40.

[23]. Odriozola-Serrano I, Oms-Oliu G, Martín-Bellows O. Nano emulsion- Based DeliverySystemstoImproveFunctionalityof LipophilicComponents.Vol.1, Front iersin Nutrition. Frontier Media S.A.;2014.

[24]. Nanostructured Lipid Carrier (NLC)- A Promising Drug Delivery for Trans dermal Application.

[25]. Barauskas J, Christerson L, Wadsäter M, Lindström F, Lindqvist AK, Tiberg F. Bioadhesive lipid compositions: Self-assembly structures, functionality, and medical applications. MolecularPharmaceutics.2014Mar 3;11(3):895–903.

[26]. Qu J, Zhang L, Chen Z, Mao G, Gao Z, Lai X, et al. Nanostructured lipid carriers, solid lipid nano particles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy? DrugDelivery.2016Nov21;23(9):3408–16.28of30.

[27]. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. International Journal of Pharmaceutics.2008Jan4;346(1–2):124–32.

[28]. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Vol. 42, Progress in Lipid Research. Elsevier Ltd;2003.p.463–78.

[29]. GabaB, Fasil M, Khan S, Ali A, Baboota S, AliJ. Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride. Bulletin of Faculty of Pharmacy, CairoUniversity.2015Dec;53(2):147–59.

[30]. Duong VA, Nguyen TTL, Maeng HJ. Preparation of solid lipid nanoparticles and nano structured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method.Vol.25, Molecules. MDPI AG;2020.

[31]. Salvi VR, Pawar P. Nanostructured lipid carriers (NLC) system: A novel drug targetingcarrier.Vol.51,Journal of Drug Delivery Science and Technology.EditionsdeSante;2019.p.255–67.

[32]. Pardeike J, Hommos's A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermalproducts.Vol.366, International Journal of Pharmaceutics.2009.p.170–84.

[33]. GarudA, v SinghD, GarudN. Solid Lipid Nanoparticles(SLN): Method, Characterization and Applications [Internet]. Vol. 2012, International Current Pharmaceutical Journal. 2012.Availablefrom:http://www.icpjonline.com/documents/Vol1Issue11/08.pdf

[34]. RibeiroLNde M, de Paula E, Rossi DA, Martins FA, de Melo RT, Monteiro GP, et al. Nano carriers From Natural Lipids With In Vitro Activity Against Campylobacter jejuni. Frontiers in Cellular and Infection Microbiology.2021Jan8;10.

[35]. Song A, Zhang X, Li Y, Mao X, Han F. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nano structure lipid carriers (NLCs) for transdermal administration. Drug

Development and IndustrialPharmacy.2016;42(8):1308–14.29of 30.

[36]. Patil D, Pattewar S, Palival S, Patil G, Sharma S. NANOSTRUCTURED LIPIDCARRIERS: A NOVEL TARGETED DRUG DELIVERY SYSTEM. International Journal of Pharmaceutical Sciences and Research [Internet]. 2020;11(10):4784. Available from: http://dx.doi.org/10.13040/IJPSR.0975-8232.11

[37]. Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, AliJ. Nano structured lipid carriers system: Recent advance sing drug delivery.Vol.20, Journal of Drug Targeting.2012.p.813–30.

[38]. Kim MH, Kim KT, Sohn SY, Lee JY, Lee CH, Yang H ,et al. Formulation and evaluation of nanostructured lipid carriers (NLCs) of 20(s)-protopanaxadiol (PPD) by box-behnken design. International Journal of Nanomedicine.2019;14:8509–20.

[39]. Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN®,NLC®,LDC®)for oral drug delivery.Vol.34,Drug Development and Industrial Pharmacy.2008.p.1394–405.

[40]. Hadinoto K, SundarEsan A, Chow WS. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform:Areview.Vol.85,European Journal of Pharmaceutics and Bio pharmaceutics. Elsevier B.V.; 2013.p.427–43.

[41]. Sánchez-LópezE,EspinaM,DoktorovovaS,SoutoEB, GarcíaML.Lipidnanoparticles(SLN, NLC): Overcoming the anatomical and physiological barriers of the eye – Part II - Ocular drug-loaded lipid nanoparticles. European Journal of Pharmaceutics andBiopharmaceutics.2017Jan1;110:58–69.

[42]. MuH, Holmris. Solid lipid nanocarrier sin drug delivery: characterization and design.Vol.15, Expert Opinion on Drug Delivery. Taylor and Francis Ltd;2018.p.771–85.30of30.

[43]. Souto EB, MüRH. Cosmetic feature sand applications of lipid nanoparticles (SLNR,NLCR).

[44]. Garcês A, Amaral MH, Sousa Lobo JM, Silva AC. Formulations based on solid lipid nanoparticles (SLN) and nano structured lipid carriers (NLC) for cutaneous use: A review.Vol.112, European Journal ofPharmaceuticalSciences.ElsevierB.V.;2018.p.159–67.

[45]. Cross D, Burmester JK. Gene Therapy for Cancer Treatment: Past, Present and Future [Internet].Vol.4,Clinical Medicine & Research. Available from :http://www.clinmedres.org

[46]. Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured lipid carriers (NLC): Apotentialdeliverysystemforbioactivefood molecules.Vol.19, Innovative Food Science and Emerging Technologies.2013.p.29–43.

[47]. Mussi S v., Torchilin VP. Recent trends in the use of lipidic nanoparticles as pharmaceutical carriers for cancer therapy and diagnostics. Journal of Materials Chemistry B. 2013 Oct21;1(39):5201–9.